TABLE 2.

Relationship between site of infection, mutant selection, antimicrobial therapy, and outcome among seven patients with bla_VIM-1-positive Enterobacter infection

Case no.	Type of infection	Mutant selection	Antibiotic regimen	Outcome
2971	Bacteremia	No	Meropenem plus amikacin	Death, septic shock
2270	Skin/soft tissue infection	No	Ciprofloxacin plus amikacin	Cure
3442	Intra-abdominal abscess	Yesa	Cefepime plus gentamicin	Relapse, therapy shifted to ciprofloxacin plus amikacin, cure
63016	Bacteremia	Yesa	Ertapenem	Breakthrough bacteremia, death
68722	Complicated urinary tract infection	Yesa	Imipenem	Relapse, therapy shifted to high doses of meropenem (2 g every 8 h), cure
67110	Complicated urinary tract infection	No	Meropenem	Relapsing infection, therapy shifted to cefepime, death
67141	Complicated urinary tract infection	Yesa	Imipenem plus levofloxacin	Relapse, therapy not changed, cure

^aIsogenic mutants had meropenem MICs of 8 mg/liter.